Related Experiment Video

Updated: Aug 15, 2026

In Vitro Modeling of Fat Deposition in Metabolic Dysfunction-Associated Steatotic Liver Disease
07:03

In Vitro Modeling of Fat Deposition in Metabolic Dysfunction-Associated Steatotic Liver Disease

Published on: July 19, 2024

Metabolic Burden and Hyperuricemia Are Associated With CKD-Related Outcomes in Individuals With and Without Steatotic

Michihiro Iwaki1, Hideki Fujii2, Yoshihiro Kamada3

  • 1Department of Gastroenterology and Hepatology, Yokohama City University Graduate School of Medicine, Yokohama, Japan.

Hepatology Research : the Official Journal of the Japan Society of Hepatology
|August 14, 2026
PubMed

Insights

Cardiometabolic abnormalities, not just steatotic liver disease (SLD), are key drivers of chronic kidney disease (CKD) outcomes. Hyperuricemia is a valuable marker for assessing kidney risk in individuals with metabolic concerns.

Area of Science:

  • Nephrology
  • Hepatology
  • Metabolic Syndrome

Background:

  • Steatotic liver disease (SLD) is linked to chronic kidney disease (CKD).
  • The independent contribution of hepatic steatosis versus cardiometabolic factors to CKD is unclear.
  • This study investigates the drivers of CKD outcomes in a large Japanese cohort.

Purpose of the Study:

  • To determine the relative impact of hepatic steatosis and cardiometabolic risk factors on CKD-related outcomes.
  • To assess the role of hyperuricemia in renal risk stratification.

Main Methods:

  • Analysis of 30,648 SLD and 76,182 non-SLD participants from the MIRACLE-J cohort (Japan, 2014-2018).
  • CKD outcomes defined as reduced estimated glomerular filtration rate (eGFR < 60 mL/min/1.73 m²) and proteinuria.
  • Multivariable logistic regression and trend analyses were employed.

Main Results:

  • SLD participants had a higher burden of cardiometabolic abnormalities.
  • Cardiometabolic factors (diabetes, obesity, hyperuricemia) were associated with proteinuria and reduced eGFR.
  • SLD itself showed an inverse association with CKD outcomes after adjustment.
  • CKD prevalence increased with the number of cardiometabolic risk factors in both SLD and non-SLD groups.
  • Hyperuricemia significantly improved risk prediction models for reduced eGFR and proteinuria.

Conclusions:

  • Cardiometabolic abnormalities are more strongly associated with CKD outcomes than SLD alone.
  • These associations are consistent across individuals with and without SLD.
  • Hyperuricemia offers incremental value for renal risk stratification within a cardiometabolic framework.
Abstract

Keywords:
chronic kidney diseasehyperuricemiaobesitysteatotic liver disease

Related Concept Videos

Pharmacokinetics in Obese Patients: Drug Metabolism and Excretion01:20

Pharmacokinetics in Obese Patients: Drug Metabolism and Excretion

Drug metabolism, a critical process in the liver, involves two primary phases: Phase I reactions and Phase II conjugation. Obesity introduces significant alterations in this metabolic process, primarily due to fatty infiltration of the liver, leading to conditions such as nonalcoholic fatty liver disease (NAFLD). This condition can modify the activities of both Phase I and II enzymes, impacting how drugs are metabolized in obese patients.Phase I metabolism sees variable effects across...
Effect of Hepatic Disease on Pharmacokinetics: Pathophysiologic Assessment and Liver Function Test01:22

Effect of Hepatic Disease on Pharmacokinetics: Pathophysiologic Assessment and Liver Function Test

In clinical practice, the direct measurement of hepatic blood flow to evaluate liver function presents significant challenges due to the intricate and specialized nature of the necessary techniques. Consequently, healthcare professionals often rely on empirical estimates derived from thorough patient examinations and liver function tests to gauge liver health. Among the tools at their disposal, the Child–Pugh and MELD scoring systems stand out for their ability to categorize and assess the...
Chronic Kidney Disease II: Clinical Manifestations01:24

Chronic Kidney Disease II: Clinical Manifestations

Chronic Kidney Disease (CKD) progressively impairs multiple body systems due to the accumulation of uremic toxins, which disrupt cellular functions across various organs.Neurologic symptomsNeurologic symptoms often arise early in CKD, as uremic toxin buildup drives changes in cognitive and motor functions. Patients frequently experience fatigue, headache, confusion, difficulty concentrating, and, in severe cases, seizures. Peripheral neuropathy commonly manifests as burning sensations in the...
Effect of Hepatic Disease on Pharmacokinetics: Drug Dosing and Hepatic Blood Flow01:26

Effect of Hepatic Disease on Pharmacokinetics: Drug Dosing and Hepatic Blood Flow

Chronic liver disease significantly impacts drug metabolism due to alterations in hepatic blood flow and enzyme accessibility. This disruption affects the body's pharmacokinetics—the movement and processing of drugs within the system. Key enzymes crucial for metabolizing medications become less accessible, changing how drugs are processed and utilized. Furthermore, liver disease influences the synthesis of plasma proteins, such as albumin and globulins, which play critical roles in drug binding...
Effect of Hepatic Disease on Pharmacokinetics: Active Drug, Metabolite and Fraction of Metabolized Drug01:14

Effect of Hepatic Disease on Pharmacokinetics: Active Drug, Metabolite and Fraction of Metabolized Drug

In pharmacotherapy, monitoring drug concentrations is paramount, especially for drugs whose therapeutic effects hinge on both the active compound and its metabolite. Hepatic impairment profoundly influences drug potency by altering liver function. If the drug is more potent than its metabolite, impaired liver function amplifies drug activity due to elevated drug concentration levels. Conversely, if the metabolite holds greater potency, diminished liver function diminishes drug activity by...
Chronic Kidney Disease III: Interprofessional Care01:28

Chronic Kidney Disease III: Interprofessional Care

Chronic kidney disease (CKD) requires collaborative and comprehensive management. CKD progresses through stages and can lead to end-stage kidney disease (ESKD) if untreated. Interprofessional collaboration and patient education are crucial, enabling patients to manage their health and improve their quality of life.Diagnostic approach for chronic kidney diseaseThe diagnosis of CKD primarily focuses on the glomerular filtration rate (GFR), which assesses kidney function by measuring how well...